Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Neurotherapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.nurt.2008.10.039PMID 19110199PMCID PMC5084256
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiglucocorticoid treatments for mood disorders.

  2015cited by this paper
• Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists.

  2009cited by this paper
• Neurokinin1 Antagonists Potentiate Antidepressant Properties of Serotonin Reuptake Inhibitors, Yet Blunt Their Anxiogenic Actions: A Neurochemical, Electrophysiological, and Behavioral Characterization

  2009cited by this paper
• Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests

  2009cited by this paper
• Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges.

  2008cited by this paper
• Circadian abnormalities, molecular clock genes and chronobiological treatments in depression.

  2008cited by this paper
• In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor.

  2008cited by this paper
• Escitalopram for the treatment of major depression and anxiety disorders

  2008cited by this paper
• A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression.

  2008cited by this paper
• Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists.

  2008cited by this paper
• A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory

  2008cited by this paper
• Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

  2008cited by this paper
• Glucocorticoid antagonists in neuropsychiatric [corrected] disorders.

  2008cited by this paper
• How can we realize the promise of personalized antidepressant medicines?

  2008cited by this paper
• Corrigendum to: Glucocorticoid antagonists in neuropsychiatric disorders [European Journal of Pharmacology 583 (2008) 358–364]

  2008cited by this paper
• Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies?

  2008cited by this paper
• 5-HT1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders.

  2008cited by this paper
• Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.

  2008cited by this paper
• Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression.

  2008cited by this paper
• Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions.

  2008cited by this paper
• Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice.

  2008cited by this paper
• What does systems biology mean for drug development?

  2008cited by this paper
• Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors.

  2008cited by this paper
• The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats.

  2008cited by this paper
• Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression.

  2008cited by this paper
• Nicotinic Antagonist Augmentation of Selective Serotonin Reuptake Inhibitor-Refractory Major Depressive Disorder: A Preliminary Study

  2008cited by this paper
• Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression?

  2008cited by this paper
• Addressing circadian rhythm disturbances in depressed patients

  2008cited by this paper
• Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds.

  2008cited by this paper
• Serotonin research: contributions to understanding psychoses.

  2008cited by this paper
• Drug Target Identification Using Side-Effect Similarity

  2008cited by this paper
• Exploiting Complexity and the Robustness of Network Architecture for Drug Discovery

  2008cited by this paper
• Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.

  2008cited by this paper
• From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.

  2008cited by this paper
• The Discovery and Development of Pharmacotherapy for Psychiatric Disorders: A Critical Survey of Animal and Translational Models and Perspectives for Their Improvement

  2008cited by this paper
• Effects of chronic desipramine treatment on alpha2-adrenoceptors and mu-opioid receptors in the guinea pig cortex and hippocampus.

  2008cited by this paper
• Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions.

  2008cited by this paper
• Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models

  2008cited by this paper
• A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XR

  2008cited by this paper
• Protein networks in disease.

  2008cited by this paper
• Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders

  2008cited by this paper
• In vivo/ex vivo and behavioural study on central effects of 5-HT1B/1D and 5-HT1A antagonists in guinea pigs.

  2008cited by this paper
• Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.

  2008cited by this paper
• P.2.b.015 Lu AA21004: a novel potential treatment for mood disorders

  2008cited by this paper
• The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats.

  2008cited by this paper
• Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models.

  2008cited by this paper
• A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory.

  2008cited by this paper
• Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.

  2008cited by this paper
• Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter.

  2008cited by this paper
• Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.

  2008cited by this paper
• Novel paradigms for drug discovery: computational multitarget screening.

  2008cited by this paper
• S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

  2008cited by this paper
• Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B)

  2008cited by this paper
• Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test.

  2008cited by this paper
• Brief treatment with the glucocorticoid receptor antagonist mifepristone normalizes the reduction in neurogenesis after chronic stress

  2007cited by this paper
• Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.

  2007cited by this paper
• Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.

  2007cited by this paper
• Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice.

  2007cited by this paper
• Relating protein pharmacology by ligand chemistry

  2007cited by this paper
• Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior.

  2007cited by this paper
• Reboxetine Combination in Treatment-resistant Depression to Selective Serotonin Reuptake Inhibitors

  2007cited by this paper
• Reduced 5-HT1A- and GABAB receptor function in dorsal raphé neurons upon chronic fluoxetine treatment of socially stressed rats.

  2007cited by this paper
• Serotonin 5-HT(2C) receptors regulate anxiety-like behavior.

  2007cited by this paper
• Small-world anatomical networks in the human brain revealed by cortical thickness from MRI.

  2007cited by this paper
• Randomised controlled trial of interpersonal psychotherapy and cognitive–behavioural therapy for depression

  2007cited by this paper
• Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor.

  2007cited by this paper
• Mifepristone Repairs Region-Dependent Alteration of Synapsin I in Hippocampus in Rat Model of Depression

  2007cited by this paper
• Glucocorticoid receptor antagonists hasten and augment neurochemical responses to a selective serotonin reuptake inhibitor antidepressant.

  2007cited by this paper
• Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites.

  2007cited by this paper
• Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms

  2007cited by this paper
• Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication?

  2007cited by this paper
• Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties.

  2007cited by this paper
• GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models

  2007cited by this paper
• Last findings on dual inhibitors of abl and SRC tyrosine-kinases.

  2007cited by this paper
• Emerging treatments for major depression

  2007cited by this paper
• Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors

  2007cited by this paper
• Selective blockade of dopamine D3 versus D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis

  2007cited by this paper
• Drug—target network

  2007cited by this paper
• Augmentation of SSRI Effects on Serotonin by 5-HT2C Antagonists: Mechanistic Studies

  2007cited by this paper
• A review of the efficacy and tolerability of agomelatine in the treatment of major depression

  2007cited by this paper
• Blockade of autoreceptor-mediated inhibition of norepinephrine release by atipamezole is maintained after chronic reuptake inhibition.

  2007cited by this paper
• Simulation of robustness against lesions of cortical networks

  2007cited by this paper
• Which antidepressants have demonstrated superior efficacy? A review of the evidence

  2007cited by this paper
• Simultaneous blockade of 5-HT1A/B receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B

  2007cited by this paper
• Proteins, drug targets and the mechanisms they control: the simple truth about complex networks

  2007cited by this paper
• The sigma‐1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus

  2007cited by this paper
• Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.

  2007cited by this paper
• Chronotherapeutics in a psychiatric ward.

  2007cited by this paper
• Pyrrolidino-tetrahydroisoquinolines bearing pendant heterocycles as potent dual H3 antagonist and serotonin transporter inhibitors.

  2007cited by this paper
• Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.

  2007cited by this paper
• GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.

  2007cited by this paper
• Stress‐induced rearrangements of cellular networks: Consequences for protection and drug design

  2007cited by this paper
• Targeted Agents: The Rules of Combination

  2007cited by this paper
• Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.

  2007cited by this paper
• Serotonin Activates the Hypothalamic–Pituitary–Adrenal Axis via Serotonin 2C Receptor Stimulation

  2007cited by this paper
• Role of GABA in anxiety and depression

  2007cited by this paper
• Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action.

  2007cited by this paper
• Selective Blockade of 5-Hydroxytryptamine (5-HT)7 Receptors Enhances 5-HT Transmission, Antidepressant-Like Behavior, and Rapid Eye Movement Sleep Suppression Induced by Citalopram in Rodents

  2007cited by this paper
• Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6 Receptor Stimulation

  2007cited by this paper
• Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival.

  2007cited by this paper

• Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human.

  2025cites this paper
• The Serotonergic System and Its Role in Thermoregulation

  2025cites this paper
• 1,3,5-Triazine: A Promising Molecular Scaffold for Novel Agents for the Treatment of Alzheimer’s Disease

  2025cites this paper
• Efficacy and safety of dextromethorphan–bupropion combination (AXS-05) in the treatment of depression: A systematic review and network meta-analysis

  2025cites this paper
• Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models

  2025cites this paper
• Rise of polycatecholamine ultrathin films: From synthesis to smart applications

  2025cites this paper
• Design and synthesis of new 1,2,3-triazole derivatives as VEGFR-2/telomerase downregulatory candidates endowed with apoptotic potential for cancer treatment.

  2025cites this paper
• Dual EGFR and telomerase inhibitory potential of new triazole tethered Schiff bases endowed with apoptosis: design, synthesis, and biological assessments.

  2024cites this paper
• Multi-target rational design and synthesis of novel diphenyl-tethered pyrazolopyrimidines targeting EGFR and topoisomerase II with potential DNA intercalation and apoptosis induction.

  2024cites this paper
• Muti-target rationale design of novel substituted N-phenyl-2-((6-phenylpyridazin-3-yl)thio)acetamide candidates as telomerase/JAK1/STAT3/TLR4 inhibitors: In vitro and in vivo investigations.

  2024cites this paper
• Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands

  2024cites this paper
• Design and synthesis of novel multi-target tetrabromophthalimides as CBS and Topo-II inhibitors and DNA intercalators.

  2024cites this paper
• Imipramine Suppresses Tumor Growth and Induces Apoptosis in Oral Squamous Cell Carcinoma: Targeting Multiple Processes and Signaling Pathways

  2023cites this paper
• Implications for Combination Therapy of Selective Monoamine Reuptake Inhibitors on Dopamine Transporters

  2023cites this paper
• Pharmacological Characterization of P626, a Novel Dual Adenosine A2A/A2B Receptor Antagonist, on Synaptic Plasticity and during an Ischemic-like Insult in CA1 Rat Hippocampus

  2023cites this paper
• Expanding the notion of mechanism to further understanding of biopsychosocial disorders? Depression and medically-unexplained pain as cases in point.

  2023cites this paper
• PEA-OXA ameliorates allodynia, neuropsychiatric and adipose tissue remodeling induced by social isolation.

  2022cites this paper
• In vitro and in vivo pharmacological characterization of dasotraline, a dual dopamine and norepinephrine transporter inhibitor in vivo.

  2022cites this paper
• Antidepressants, Sexual Behavior, and Translational Models for Male Sexual Dysfunction: Development of Animal Models, Pharmacology, and Genetics

  2022cites this paper
• A new paradigm shift in antidepressant therapy? From dual-action to multitarget-directed ligands.

  2022cites this paper
• Prevention of Stress-Induced Depressive-like Behavior by Saffron Extract Is Associated with Modulation of Kynurenine Pathway and Monoamine Neurotransmission

  2021cites this paper
• Antidepressant-like effect of Campomanesia xanthocarpa seeds in mice: Involvement of the monoaminergic system

  2021cites this paper
• Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses.

  2021cites this paper
• Single Molecule Non-cleavable Multiply Active Antibacterials

  2021cites this paper
• A Bird's-Eye View of Exercise Intervention in Treating Depression Among Teenagers in the Last 20 Years: A Bibliometric Study and Visualization Analysis

  2021cites this paper
• Device-Based Modulation of Neurocircuits as a Therapeutic for Psychiatric Disorders.

  2020cites this paper
• University of Birmingham Central 5-HT receptors and their function ; present and future

  2020cites this paper
• Central 5-HT receptors and their function; present and future.

  2020cites this paper
• The binding mode of vilazodone in the human serotonin transporter elucidated by ligand docking and molecular dynamics simulations.

  2020cites this paper
• Synthesis and antidepressant effect of novel aralkyl piperazine and piperidine derivatives targeting SSRI/5-HT1A/5-HT7.

  2019cites this paper
• Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands.

  2019cites this paper
• Synthesis and antidepressant-like activity of novel alkoxy-piperidine derivatives targeting SSRI/5-HT1A/5-HT7.

  2019cites this paper
• Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands.

  2019cites this paper
• Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.

  2019cites this paper
• Triple reuptake inhibitors (TRIs): do they promise us a rose garden?

  2018cites this paper
• Neuropeptide and Small Transmitter Coexistence: Fundamental Studies and Relevance to Mental Illness

  2018cites this paper
• The role of aryl-topology in balancing between selective and dual 5-HT7R/5-HT1A actions of 3,5-substituted hydantoins.

  2018cites this paper
• Pharmacological characterization of (3-(benzo[d][1,3] dioxol-4-yloxy) -3-(4-fluorophenyl)-N, N-dimethylpropan-1-amine (H05), a novel serotonin and noradrenaline reuptake inhibitor with moderate 5-HT2A antagonist activity for the treatment of depression Authors:

  2018cites this paper
• Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression

  2018cites this paper
• Synthesis and antidepressant-like activity of novel aralkyl piperazine derivatives targeting SSRI/5-HT1A/5-HT7.

  2018cites this paper
• Design, synthesis and docking study of 4-arylpiperazine carboxamides as monoamine neurotransmitters reuptake inhibitors.

  2018cites this paper
• Computational Modeling of Multi-target-Directed Inhibitors Against Alzheimer’s Disease

  2018cites this paper
• THERAPEUTIC EFFICACY OF COMBINATION THERAPY OF L-METHYLFOLATE AND ESCITALOPRAM IN DEPRESSION

  2017cites this paper
• Serotonin transporter and receptor ligands with antidepressant activity as neuroprotective and proapoptotic agents

  2017cites this paper
• Synthesis and antidepressant activity of a series of arylalkanol and aralkyl piperazine derivatives targeting SSRI/5-HT1A/5-HT7.

  2017cites this paper
• New Trends in Antidepressant Drug Research

  2017cites this paper
• Methylene blue and its analogues as antidepressant compounds

  2017cites this paper
• EDITORIAL OF THE SPECIAL ISSUE : NEUROBIOLOGY AND NEUROPHARMACOLOGY OF MONOAMINERGIC SYSTEMS

  2017cites this paper
• Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors.

  2017cites this paper
• Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors

  2017cites this paper
• Triple reuptake inhibitors: Design, synthesis and structure-activity relationship of benzylpiperidine-tetrazoles.

  2017cites this paper
• Neurobiology and neuropharmacology of monoaminergic systems.

  2017cites this paper
• Tailored Multi-Target Agents. Applications and Design Considerations.

  2016cites this paper
• [Sequential prescriptions: Arguments for a change of therapeutic patterns in treatment resistant depressions].

  2016cites this paper
• Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study.

  2016cites this paper
• The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

  2016cites this paper
• The influence of 5-HT(2A) activity on a 5-HT(2C) specific in vivo assay used for early identification of multiple acting SERT and 5-HT(2C) receptor ligands.

  2016cites this paper
• Perspectives in Designing Multifunctional Molecules in Antipsychotic Drug Discovery

  2016cites this paper
• Computational approaches for innovative antiepileptic drug discovery

  2016cites this paper
• Design, synthesis, and biological evaluation of arylpiperazine-benzylpiperidines with dual serotonin and norepinephrine reuptake inhibitory activities.

  2016cites this paper
• Charting the chemical space around the (iso)indoline scaffold, a comprehensive approach towards multitarget directed ligands.

  2016cites this paper
• Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders.

  2016cites this paper
• Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study

  2016cites this paper
• The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders

  2016influential citation
• Prescriptions séquentielles : arguments en faveur d’une modification des schémas thérapeutiques dans les dépressions résistantes

  2016cites this paper
• Competitive Intelligence–based Lead Generation and Fast Follower Approaches

  2016cites this paper
• Involvement of monoaminergic system in the antidepressant-like effect of (octylseleno)-xylofuranoside in the mouse tail suspension test.

  2016cites this paper
• Effects of female gonadal hormones and LPS on depressive-like behavior in rats

  2015cites this paper
• Preparation of (S)-4-(1-(3,4-dichlorophenyl)-2-methoxyethyl)piperidine

  2015cites this paper
• The Historical Development of Immunoendocrine Concepts of Psychiatric Disorders and Their Therapy

  2015cites this paper
• Angelica gigas ameliorate depression-like symptoms in rats following chronic corticosterone injection

  2015cites this paper
• Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs.

  2015cites this paper
• Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.

  2015cites this paper
• Commentary: obstacles to the discovery of medicines for psychiatric disorders in modern times.

  2015cites this paper
• Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.

  2015cites this paper
• Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. Part 4.

  2015cites this paper
• Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders.

  2015cites this paper
• Serotonin: a never-ending story.

  2015cites this paper
• Role of the Endocannabinoid System in Depression: from Preclinical to Clinical Evidence

  2015cites this paper
• Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

  2015cites this paper
• Kombinace antidepresiv v léčbě deprese: Doporučení a klinickápraxe

  2015cites this paper
• The Effect of Data Curation on the Accuracy of Quantitative Structure-Activity Relationship Models

  2015cites this paper
• Design and synthesis of 4-benzylpiperidine carboxamides as dual serotonin and norepinephrine reuptake inhibitors.

  2015cites this paper
• Back to the future of psychopharmacology: A perspective on animal models in drug discovery.

  2015cites this paper
• Antidepressant drug development: Focus on triple monoamine reuptake inhibition

  2015cites this paper
• Synthesis and Biological Screening of Novel Indolalkyl Arenes Targeting the Serotonine Transporter

  2014cites this paper
• Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.

  2014cites this paper
• Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.

  2014cites this paper
• History, background, concepts and current use of comedication and polypharmacy in psychiatry.

  2014cites this paper
• The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats

  2014cites this paper
• An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets

  2014cites this paper
• Design, Synthesis, and Optimization of Balanced Dual NK1/NK3 Receptor Antagonists.

  2014cites this paper
• Schnappschuss von Antidepressiva bei der Arbeit: die Struktur von Neurotransmittertransporter‐Proteinen

  2014cites this paper
• Polypharmacology: the rise of multitarget drugs over combination therapies.

  2014cites this paper
• Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank.

  2014cites this paper
• Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.

  2014cites this paper
• Design of novel multiple-acting ligands towards SERT and 5-HT2C receptors.

  2014cites this paper
• Editorial Sp E cial Focu S: Horizon S in ME dicinal cHEM i S try

  2014cites this paper
• Triple reuptake inhibitors: a patent review (2006 – 2012)

  2014cites this paper
• Novel therapeutic strategies in major depression: focus on RNAi and ketamine.

  2014cites this paper